Furthermore, we observed the RET variant (rs1800861, COSM4418405) in 98% of patients, reaching 100% prevalence in advanced-stage of HCC, mirroring its known associations with adamantinomatous craniopharyngioma (Jastania et al., 2020), thyroid cancer (Minna et al., 2022) and chronic myeloid leukemia (Sklarz et al., 2018). Here, RET is linked to thyroid cancer.